AR and prostate cancer: Our present findings show that TLX can directly target and repress the AR gene promoter, and also suppress the ligand-activated transcriptional activity of AR in prostate cancer cells, and through which it could enhance the NED progression and stemness of PCSCs in subpopulations of CRPC.